We recently compiled a list of the 10 Best Guru Stocks To Buy Now. In this article, we will have a look at where Roivant ...
Selling plaque psoriasis drug Vtama to Organon looks like another win for Roivant, which has been buying overlooked drugs, ...
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant for up to $1.2 billion, the companies announced ...
Organon & Co (NYSE:OGN) has agreed to acquire Roivant Sciences Ltd’s (NASDAQ:ROIV) Dermavant Sciences Ltd, which is focused ...
The Roivant company is dedicated to developing and commercializing innovative therapeutics in immune-dermatology.
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Bluebird Bio (BLUE – Research Report), ...
Organon is set to acquire Roivant’s immuno-dermatology subsidiary Dermavant in a potential $1.2bn deal. Organon will pay $175m upfront for the business as part of the transaction, which is ...